NTLA vs CRSP
NTLA and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $1.72B | $5.55B |
| P/S | 25.4x | 1579.9x |
| Revenue growth (YoY) | 16.9% | -90.6% |
| Earnings growth (YoY) | 20.5% | -58.8% |
| EBIT margin | -651.7% | -18933.6% |
| ROE | -56.7% | -33.3% |
| ROIC | — | -32.6% |
| 1y total return | -1.1% | -2.9% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: NTLA vs CRSP
| Metric | NTLA | CRSP |
|---|---|---|
| End value | $9.7K | $40.7K |
| Total return | -2.8% | +306.9% |
| CAGR | -0.3% | +15.2% |
| Volatility | 78.6% | 64.1% |
| Sharpe | 0.34 | 0.47 |
| Sortino | 0.50 | 0.73 |
| Max drawdown | -96.5% | -85.1% |
Based on 2491 common trading days, 2016-10-19 → 2026-09-17 · risk-free 4.12% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)